Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019019 | 1.00 | GABRA1 (0.38) | GABRA1GABRG2GABRB3PDCD1CD274 | |
| SCHEMBL787338 | 1.00 | GABRA1 (0.38) | GABRA1GABRG2GABRB3PDCD1CD274 | |
| SCHEMBL30724484 | 1.00 | GABRA1 (0.38) | GABRA1GABRG2GABRB3PDCD1CD274 | |
| SCHEMBL787933 | 1.00 | GABRA1 (0.38) | GABRA1GABRG2GABRB3PDCD1CD274 | |
| SCHEMBL29626322 | 1.00 | GABRA1 (0.38) | GABRA1GABRG2GABRB3PDCD1CD274 | |
| SCHEMBL9518132 | 0.87 | GABRA1 (0.33) | GABRA1GABRG2GABRB3CYP1A2CYP3A4 | |
| SCHEMBL24658618 | 0.87 | ADRA2A (0.33) | GABRA1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL24658889 | 0.87 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL20880768 | 0.85 | GABRA1 (0.35) | GABRA1GABRG2GABRB3 | |
| SCHEMBL19559589 | 0.84 | PDCD1 (0.34) | GABRA1GABRG2GABRB3PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228823-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2025-07-17 | — | — | US | claimed |
| US-20220233505-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALLERGAN, INC. | 2022-07-28 | — | — | US | claimed |
| US-11331306-B2 | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases | ALLERGAN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| US-20220008393-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2022-01-13 | — | — | US | claimed |
| EP-3795154-A1 | PHARMACEUTICAL COMPOSITION COMPRISING (S)-(3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL FOR USE IN TREATING OCULAR CONDITIONS | Allergan, Inc. (US) | 2021-03-24 | — | — | EP | claimed |
| EP-3093017-B1 | PHARMACEUTICAL COMPOSITION COMPRISING (S)-(3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL FOR TREATING OPTIC NEUROPATHY | ALLERGAN INC (US) | 2021-01-06 | — | — | EP | claimed |
| US-20200390747-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALLERGAN INC (US) | 2020-12-17 | — | — | US | claimed |
| US-20200206193-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN INC (US) | 2020-07-02 | — | — | US | claimed |
| US-10555933-B2 | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases | ALLERGAN, INC. (US) | 2020-02-11 | — | — | US | claimed |
| US-20190240200-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALLERGAN INC (US) | 2019-08-08 | — | — | US | claimed |
| US-9095576-B2 | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases | ALLERGAN, INC. (US) | 2015-08-04 | — | — | US | claimed |
| EP-2782569-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2014-10-01 | — | — | EP | claimed |
| EP-2734200-A1 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE | Allergan, Inc. (US) | 2014-05-28 | — | — | EP | claimed |
| EP-2640382-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | Allergan, Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| WO-2013078151-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2013-05-30 | — | — | WO | claimed |
| US-20130131133-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2013-05-23 | — | — | US | claimed |
| WO-2013016073-A1 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE | ALLERGAN, INC. (US) | 2013-01-31 | — | — | WO | claimed |
| US-20130023573-A1 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE | ALLERGAN, INC. | 2013-01-24 | — | — | US | claimed |
| US-20120149747-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2012-06-14 | — | — | US | claimed |
| WO-2012067941-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2012-05-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023573-A1 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE | ADRB2, ADRA2C, ADRA2A | GABRA1 99/4885GABRG2 334/4885GABRB3 75/4885 |
| US-11331306-B2 | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases | ALDH1A2, PDE6D, NR2E3 | GABRA1 1463/4885GABRG2 796/4885GABRB3 186/4885 |
| US-20220008393-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | MAPT, REN, MYLK | GABRA1 2276/4885GABRG2 2737/4885GABRB3 1807/4885 |
| US-20120149747-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | MAPT, REN, MYLK | GABRA1 2276/4885GABRG2 2737/4885GABRB3 1807/4885 |
| US-20130131133-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALDH1A2, PDE6D, NR2E3 | GABRA1 1458/4885GABRG2 730/4885GABRB3 167/4885 |
| US-20190240200-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALDH1A2, PDE6D, NR2E3 | GABRA1 1458/4885GABRG2 730/4885GABRB3 167/4885 |
| US-10555933-B2 | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases | ALDH1A2, PDE6D, NR2E3 | GABRA1 1458/4885GABRG2 730/4885GABRB3 167/4885 |
| US-20220233505-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALDH1A2, PDE6D, NR2E3 | GABRA1 1458/4885GABRG2 730/4885GABRB3 167/4885 |
| US-20200390747-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES | ALDH1A2, PDE6D, NR2E3 | GABRA1 1463/4885GABRG2 796/4885GABRB3 186/4885 |
| US-20250228823-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | HMGCR, REN, MAPT | GABRA1 2378/4885GABRG2 2715/4885GABRB3 1535/4885 |
| US-20200206193-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | MAPT, REN, MYLK | GABRA1 2276/4885GABRG2 2737/4885GABRB3 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.